Login to Your Account

Dezima mulls options for outcomes trial as phase IIb data impress

By Cormac Sheridan
Staff Writer

Thursday, June 4, 2015

DUBLIN – Newly published efficacy data for TA-8995, Dezima Pharma BV's cholesterol ester transfer protein (CETP) inhibitor, confirmed the company's claim last year that it may have in its hands the most potent molecule in that emerging drug class of cholesterol control agents.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription